487 Shares in Solventum Co. (NYSE:SOLV) Purchased by Crews Bank & Trust

Crews Bank & Trust bought a new position in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 487 shares of the company’s stock, valued at approximately $32,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC bought a new stake in Solventum during the fourth quarter worth $35,000. Forsta AP Fonden purchased a new stake in shares of Solventum during the 4th quarter valued at $1,876,000. Robeco Institutional Asset Management B.V. raised its stake in shares of Solventum by 3.1% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 28,694 shares of the company’s stock worth $1,896,000 after purchasing an additional 868 shares during the period. KBC Group NV boosted its holdings in shares of Solventum by 725.3% in the 4th quarter. KBC Group NV now owns 234,933 shares of the company’s stock worth $15,520,000 after buying an additional 206,466 shares during the last quarter. Finally, Blue Trust Inc. grew its position in Solventum by 2.1% during the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after buying an additional 161 shares during the period.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of research reports. Mizuho began coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. Finally, Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average price target of $68.29.

Solventum Price Performance

Shares of NYSE:SOLV opened at $74.05 on Friday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The firm has a fifty day moving average price of $70.17 and a two-hundred day moving average price of $67.21. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. As a group, equities analysts anticipate that Solventum Co. will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.